LifeMD, Inc. (NASDAQ:LFMD ) Q4 2024 Results Conference Call March 10, 2025 4:30 PM ET Company Participants Justin Schreiber - Chairman and Chief Executive Officer Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG Steve Dechert - KeyBanc Brooks O'Neil - Lake Street Capital Markets Steven Valiquette - Mizuho Securities Alex Fuhrman - Craig-Hallum Capital Group Sarah James - Cantor Anderson Schock - B. Riley Securities Operator Good afternoon.
Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60% Adjusted EBITDA increased 78% to $9.0 million Telehealth adjusted EBITDA increased 396% to $5.9 million Full-year cash flow from operations increased 99% to $17.5 million and generated positive full-year net cash flow Exited 2024 with over $35 million in cash Introduces 2025 guidance for consolidated revenue of $265 million to $275 million and consolidated adjusted EBITDA of $30 million to $32 million Conference call begins at 4:30 p.m. Eastern time today NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and 12 months ended December 31, 2024.
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced it is integrating with LillyDirect pharmacy provider, Gifthealth, to offer streamlined access of single-dose vials of Lilly's prescription obesity treatment Zepbound® (tirzepatide) to eligible LifeMD patients. Integration with the LillyDirect ® self-pay pharmacy channel will provide a seamless solution to a patient's Zepbound fulfillment journey while continuing to offer more accessible pricing and direct shipment to patients.
Expansion to Include Teletherapy, Psychiatry and Medication Management Behavioral Health Offering to be Led by Industry Veteran Julian Cohen NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its expansion into the behavioral health market. This strategic move broadens LifeMD's service offerings to include teletherapy, psychiatry and medication management for common mental health conditions.
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 11-12, 2025, at the Cliff Lodge in Snowbird, Utah. Management will hold one-on-one meetings throughout the conference.
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.
LifeMD, Inc. (NASDAQ:LFMD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financial Officer Conference Call Participants David Larsen - BTIG Sarah James - Cantor Fitzgerald Kyle Bauser - B. Riley Securities Steve Dechert - KeyBanc Eduardo Martinez-Montes - H.C.
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.20 per share a year ago.
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.